图书馆订阅: Guest
肿瘤形成评论综述™

每年出版 4 

ISSN 打印: 0893-9675

ISSN 在线: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers

卷 22, 册 5-6, 2017, pp. 507-514
DOI: 10.1615/CritRevOncog.2017020577
Get accessGet access

摘要

Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare malignant tumors. The mainstay of treatment patients with TET is surgical resection, and chemotherapy is necessary for patients with tumor invasion or metastasis who are unable to undergo complete radical excision. However, for those patients who are resistant to chemotherapy, targeted therapy has become the most popular tumor treatment program, as well as for thymic tumors. Many genes implicated in tumorigenesis and metastasis have also been reported to be therapeutic targets in thymic malignancies. A significant advance in TET treatment may derive from the identification of novel molecular biomarkers that can improve the diagnosis, prognosis, and treatment of tumors. We review a number of case reports and small clinical trials reporting that a few inhibitors, such as sorafenib and sunitinib, are effective in the treatment of thymoma. In this review, we describe the current potential drug targets and their roles in the development of thymic malignancy.

对本文的引用
  1. Feng Feiling, Wu Xiaobing, Shi Xiaoliang, Gao Qingxiang, Wu Yue, Yu Yong, Cheng Qingbao, Li Bin, Yi Bin, Liu Chen, Hao Qing, Zhang Lin, Gao Chunfang, Jiang Xiaoqing, Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients, International Journal of Clinical Oncology, 26, 4, 2021. Crossref

Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集 订购及政策 Begell House 联系我们 Language English 中文 Русский Português German French Spain